Evoke, Eversana Announce Positive Data For Gimoti In Diabetic Gastroparesis Patients On GLP-1

(RTTNews) - Evoke Pharma Inc. (EVOK) and Eversana Life Science Services, LLC. announced statistically significant comparative data on its study of Gimoti nasal spray as a potential supportive care in diabetic gastroparesis patients using Glucagon-like peptide-1 or GLP-1.

GLP-1 is a hormone that helps regulate blood sugar levels and appetite and diabetic gastroparesis is a condition that delays gastric emptying due to nerve damage resulting from high blood sugar.

The data was presented at the American College of Gastroenterology, 2024 annual meeting.

The study compared healthcare resource utilization in patients with Gimoti and oral metoclopramide. The data observed a reduction in outcomes in patients treated with Gimoti versus oral metoclopramide. Healthcare visits were comparatively fewer in GLP-1 patients.

Currently, Evoke's stock is trading at $8.85, up 72.50 percent on the Nasdaq.